Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.41 EUR
−7.59 M EUR
0.00 EUR
14.26 M
About MIRA Pharmaceuticals, Inc.
Sector
Industry
CEO
Erez Aminov
Website
Headquarters
Miami
Founded
2020
ISIN
US60458C1045
FIGI
BBG01NZL3H93
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. It engages in developing its product candidates, Ketamir-2 and MIRA-55, designed to address unmet medical needs in pain management, depression, PTSD, and cognitive function. The company was founded by Adam Kaplin on September 3, 2020 and is headquartered in Miami, FL.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of K6S is 1.13 EUR — it has decreased by −0.88% in the past 24 hours. Watch MIRA Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange MIRA Pharmaceuticals, Inc. stocks are traded under the ticker K6S.
K6S stock has risen by 8.65% compared to the previous week, the month change is a −3.42% fall, over the last year MIRA Pharmaceuticals, Inc. has showed a 17.10% increase.
We've gathered analysts' opinions on MIRA Pharmaceuticals, Inc. future price: according to them, K6S price has a max estimate of 15.58 EUR and a min estimate of 15.58 EUR. Watch K6S chart and read a more detailed MIRA Pharmaceuticals, Inc. stock forecast: see what analysts think of MIRA Pharmaceuticals, Inc. and suggest that you do with its stocks.
K6S stock is 4.59% volatile and has beta coefficient of 0.86. Track MIRA Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is MIRA Pharmaceuticals, Inc. there?
Yes, you can track MIRA Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
MIRA Pharmaceuticals, Inc. is going to release the next earnings report on Dec 3, 2025. Keep track of upcoming events with our Earnings Calendar.
K6S earnings for the last quarter are −0.08 EUR per share, whereas the estimation was −0.08 EUR resulting in a 0.00% surprise. The estimated earnings for the next quarter are −0.08 EUR per share. See more details about MIRA Pharmaceuticals, Inc. earnings.
MIRA Pharmaceuticals, Inc. revenue for the last quarter amounts to 0.00 EUR, matching the estimated figure, and no changes in revenue are expected for the next quarter.
K6S net income for the last quarter is −1.31 M EUR, while the quarter before that showed −1.65 M EUR of net income which accounts for 20.83% change. Track more MIRA Pharmaceuticals, Inc. financial stats to get the full picture.
No, K6S doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 28, 2025, the company has 5 employees. See our rating of the largest employees — is MIRA Pharmaceuticals, Inc. on this list?
Like other stocks, K6S shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MIRA Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MIRA Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MIRA Pharmaceuticals, Inc. stock shows the neutral signal. See more of MIRA Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.